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Abstract: Although only recently introduced, chemically-modiﬁ ed hyaluronic acid dermal 
ﬁ llers have gained widespread acceptance as “redeﬁ ning” dermal ﬁ llers in the ﬁ elds of 
dermatology and cosmetic facial surgery. Although hyaluronic acid-based dermal ﬁ llers have 
a low overall incidence of long term side effects, occasional adverse outcomes, ranging from 
chronic lymphoplasmacytic inﬂ ammatory reactions to classic foreign body-type granulomatous 
reactions have been documented. These long-term adverse events are reviewed.
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Introduction
A major goal of cosmetic surgeons, dermatologists and pharmaceutical companies has 
been the development of biocompatible materials with prolonged clinical longevity 
for use as esthetic facial soft tissue augmentation agents. Ideal properties of soft tissue 
ﬁ llers include biocompatibility (low risk of foreign body-type reaction), reasonable 
clinical appearance and duration, ease of use and minimal tendency to migrate to 
distant sites.
Currently available materials can be broadly subcategorized as nonbiodegradable 
(permanent) or biodegradable (temporary). The biodegradable materials can be 
further subdivided into those of intermediate or long duration. Examples of per-
manent materials include liquid silicone (eg, Silikon®), solid silicon particles in 
suspension (eg, Bioplastique®), polymethyl methacrylate microspheres with bovine 
collagen (eg, Artecoll®), acrylic hydrogel particles with unmodiﬁ ed hyaluronic acid 
(eg, Dermalive®), calcium hydoxylapatite (eg, Radiesse®, formerly called Radiance), 
and various polyacrylamide gel formulations (eg, Aquamid®). Many of these 
permanent ﬁ llers are associated with a deﬁ nite risk of delayed foreign body-type 
reactions (Vargas-Machuca et al 2006). Biodegradable materials include polylactic 
acid microspheres (eg, New-Fill®), allogeneic human collagen from tissue culture 
(eg, CosmoDerm®), autologous fat and collagen grafts, and xenogeneic material 
such as bovine collagen (eg, Zyderm®) and glutaraldehyde-treated bovine collagen 
(eg, Zyplast®). Until recently, bovine collagen was regarded as the “gold standard” in 
facial soft tissue augmentation. However, the use of bovine collagen is associated with 
a 3%–5% risk of delayed hypersensitivity reactions (Lowe et al 2001), necessitating 
double skin testing prior to treatment (Narins et al 2003).
To date, no universally applicable dermal ﬁ ller has been developed, although 
manufacturers of hyaluronic acid-based products claim that their products are close to 
fulﬁ lling many of the requirements of an ideal tissue augmentation agent. Based on the 
rapid acceptance of these materials by both clinicians and patients, it would appear that 
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many practitioners believe that there may be some validity to 
these claims. Hyaluronic acid-based temporary dermal ﬁ llers 
are being employed with increasing frequency for the treat-
ment of facial skin lines and for lip augmentation procedures 
(Carruthers and Carruthers 2003). It is estimated that in the 
United States in 2004 alone, 878,000 patients were treated 
with hyaluronic acid-based ﬁ llers (Matarasso et al 2006), 
both animal source (Hylaform, Biomatrix Inc., Ridgeﬁ eld, 
NJ; a hyaluronic acid extract derived from rooster combs) 
and nonanimal source (Restylane®, Q-Medical Corporation, 
Uppsala, Sweden; a cross-linked hyaluronic acid injectable 
ﬁ ller produced from bacteria by microbiologic engineering 
techniques).
As stated by Walker (2006), although the aging process 
itself has been extensive researched, “there is a paucity of 
data and peer-reviewed papers on human responses to inter-
ventions in aging,” much of which involves “replacement 
therapy”. This paper will review the potential long-term side 
effects associated with the use of cross-linked hyaluronic 
acid injectable ﬁ llers as replacement therapy in dermatology/
plastic surgery.
Structure and biochemistry
of hyaluronic acid
Glycosaminoglycans (GAGs), also referred to as muco-
polysaccharides, are large negatively-charged unbranched 
polymers composed of pairs of repeating sugar units, 
one of which is an amino sugar. The main GAGs include 
chondriotin-4-sulphate, chondroitin-6-sulfate, dermatan sul-
fate, heparan sulfate, keratan sulfate, heparin, and hyaluronic 
acid. Of these, hyaluronic acid (hyaluronan), consisting of 
repeating units of the monosaccharide D-glucuronic acid and 
the amino sugar N-acetyl-D-glucosamine linked together 
via alternating beta-1,4 and beta-1,3 glycosidic bonds, is the 
most prevalent. It has been estimated that the average 60 kg 
human body contains 12 g of hyaluronic acid (Matarasso 
et al 2006). Polymers of hyaluronan can range in size from 
4,000 to 20,000,000 Daltons in vivo.
Synthesis and degradation
of hyaluronic acid
In the extracellular matrix (ECM), hyaluronic acid is pro-
duced predominantly by fibroblasts through a complex 
of cytoplasmic proteins on the plasma membrane called 
hyaluronan synthases and is extruded through the plasma 
membrane into the extracellular space. Hyaluronan is 
ultimately degraded in a step-wise manner by a family of 
hyaluronidase enzymes (Stern 2003). The ﬁ rst step in the 
process is the cleavage of high molecular weight hyaluronic 
acid to 20 kDa fragments. These fragments are further 
degraded into smaller units, primarily tetrasaccharides. These 
different-sized hyaluronic acid molecules have varying bio-
logical effects.
Function of hyaluronic acid
HA is a major component of the ECM of the dermis, where 
it is a major contributor to the formation a resilient gel-like 
ground substance that resists compressive forces.
The traditional view of hyaluronic acid as simply being 
an inert “ﬁ ller” material has recently been questioned (Stern 
2003). Hyaluronic acid contributes to tissue hydrodynamics 
by creating space for the movement of cells. Hyaluronic acid 
is believed to regulate the diffusion of nutrients, metabolites, 
and hormones between cells, and stimulates ﬁ broblast prolif-
eration, migration and collagen production. Hyaluronic acid 
also regulates cell proliferation and motility by regulating 
cell/cell and cell/matrix interactions through the cell mem-
brane receptor CD44 (Stern 2003).
The high molecular weight hyaluronic acid molecules 
have anti-inﬂ ammatory, anti-angiogenic, and immunosup-
pressive properties, whereas the 20 kDa fragments and the 
very low molecular weight hyaluronic acid degradation 
products stimulate the synthesis of new blood vessels, 
inﬂ ammatory cytokines and induce inﬂ ammatory responses 
in macrophages and dendritic cells secondary to infection 
and tissue injury.
Hyaluronic acid is present in high concentrations in 
embryonic tissue and in malignant neoplasms. Overexpres-
sion of CD44 has been linked to the growth of a number 
of malignant neoplasms, and in some cancers, hyaluronan 
levels correlate with poor prognosis. Hyaluronic acid likely 
contributes to tumor growth via its interaction with the CD44 
receptor (Hill et al 2006).
Medical applications of hyaluronic 
acid
The widespread tissue distribution of hyaluronic acid, being 
a major component of tissue ranging from skin and carti-
lage to vitreous humor, accounts in part for the potential of 
hyaluronic acid as a universal soft tissue replacement mate-
rial. Another beneﬁ t of hyaluronic acid is that, in contrast 
to collagen, its chemical structure is reportedly identical 
across different species (Richter et al 1979). Therefore, the 
risk of imunogenicity to hyaluronic acid-derived products is 
believed to be low. In addition, as a result of its water-binding 
afﬁ nity, hyaluronic acid forms a high viscosity hydrated 
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polymer that purportedly maintains much of its volume by 
binding additional molecules of water as it degrades.
The ﬁ rst hyaluronic acid-based biomedical product, 
Healon, was developed as an ophthalmic-surgical aid for 
use in various anterior segment procedures, as a vitreous 
replacement after vitrectomy and in retinal detachment 
surgery. Hyaluronic acid has also been used in the treat-
ment of osteoarthritis of the knee as a joint ﬂ uid supplement, 
typically administered by injection into the knee joint.
The process of aging is characterized by loss of resiliency 
and atrophy of underlying adipose tissue. A progressive 
reduction in hyaluronic acid content has been described in 
aging skin (Ghersetich et al 1994), leading to the suggestion 
that variations of hyaluronic acid levels in the dermis may 
account for some of the changes seen in aged skin, including 
decreased turgidity, wrinkling, and decreased elasticity. In 
view of these observations and the fact that hyaluronic acid 
is a major contributor to the extracellular matrix of the der-
mis, hyaluronic acid-derived products have been extensively 
investigated as injectable dermal supplements. The principal 
drawback with puriﬁ ed hyaluronic acid dermal ﬁ ller is the 
short half-life of hyaluronic acid in the dermis, estimated at 
24–48 hours. In order to increase the longevity of hyaluronic 
acid to the point that it is practical for clinical use, pharma-
ceutical companies have developed longer lasting hyaluronic 
acid formulations through chemical cross-linking.
Hyaluronic acid-derived dermal ﬁ llers have been avail-
able in Europe since 1996 (Andre et al 2005). The ﬁ rst 
chemically-modiﬁ ed hyaluronic acid ﬁ ller approved by 
the US Food and Drug Administration (FDA) for the cor-
rection of moderate to severe wrinkles and skin folds was 
Restylane, approved in December 2003. Chemically modi-
ﬁ ed hyaluronic acid formulations currently available in the 
United States include the nonanimal source hyaluronic 
acid (NASHA) materials: Restylane, Restylane Fine Line, 
Restylane Perlane, Restylane SubQ, Juvederm (Inamed Cor-
poration, Santa Barbara, California) and Captique (Inamed 
Corporation, Santa Barbara, California). The FDA has also 
approved a line of animal-derived hyaluronic acid products: 
Hylaform Regular, Hylaform Fine and Hylaform Plus. Dif-
ferences between these formulations include hyaluronic 
acid source, particle size, degree of cross-linking, and con-
centration of hyaluronic acid. Hylaform is cross-linked by 
glutaraldehyde vinyl sulfone, whereas Restylane is stabilized 
by treatment with 1,4-butandiol diglycidylether. The con-
centration of hyaluronic acid in Restylane is approximately 
four-fold that in Hylaform; 20 mg/ml versus 5.5 mg/ml 
(Patel et al 2006).
In addition to the correction of moderate to severe 
wrinkles and skin folds, hyaluronic acid-based dermal ﬁ llers 
are also widely used for the correction of scars and for lip 
augmentation. Intradermal injection of hyaluronic acid is 
contraindicated in patients with autoimmune disorders, on 
immunosuppressive therapy, in patients with active herpetic 
lesions, and in patients with acneiform lesions.
Because of their limited half-life, most patients require 
at least twice yearly injections of chemically-modified 
hyaluronic acid products. Some (Hamra 2006) have argued 
that, from a long-term economic perspective, patients may 
be better served by conventional plastic surgery in certain 
clinical scenarios.
Adverse reactions to hyaluronic 
acid-derived dermal fi llers
Adverse reactions to any type of surgical intervention/
replacement therapy can be divided into immediate-to-short 
term, those occurring within the first 1–2 weeks, and 
long-term, those occurring several weeks to months after 
the original intervention. Short duration local injection site 
reactions, generally resulting from an acute inﬂ ammatory 
response to tissue damage combined with the introduction 
of a foreign material, include swelling, pain, tenderness 
and bruising, and are seen in the vast majority of patients 
treated with injectable hyaluronic acid derivatives (Narins 
et al 2003). In general, lip augmentation is associated with 
the highest incidence of post-injection pain, swelling, and 
bruising. In addition, recurrent herpes labialis occurs in 
a percentage of patients following lip augmentation with 
NASHA. Consequently, many clinicians prescribe oral 
prednisone and/or systemic antiviral agents to reduce 
the severity of swelling and to reduce the incidence of 
developing recurrent herpetic lesions when performing lip 
injections.
Although much less common, more serious immediate 
onset reactions have included the development of injection site 
ulcers following inadvertent arterial occlusion (eg, Schanz 
et al 2002; Lowe 2003; Hirsch et al 2007), especially when 
injecting in the glabellar area. A protocol has been sug-
gested to manage patients who develop signs indicative of 
impending vascular occlusion (Glaich et al 2006). Visual 
disturbances have also been described following retinal 
branch artery occlusion secondary to hyaluronic acid injec-
tion (Peter and Mennel 2006). One case of angioedema-like 
swelling of the lip following injection of Restylane was 
documented (Leonhardt et al 2005), although others have 
suggested that this phenomenon is very common following 
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injection of Restylane into the lips and does not represent a 
true angioedema reaction (Klein 2005).
Late infections following hyaluronic acid injection are 
rare. Toy and Frank (2003) described two women in New 
York who developed granulomatous infections following 
injections of a non-FDA approved hyaluronic acid deriva-
tive (Hyacell) imported from South America. Both women 
were injected by the same practitioner, who was practic-
ing medicine without a license. This practitioner was 
ultimately tied to a cluster of Mycobacterium abscessus 
infections, presumably related to injections with tainted 
hyaluronic acid.
The overall incidence of long term adverse reactions 
secondary to the dermal injection of hyaluronic acid skin 
ﬁ llers is believed to be low, the vast majority representing a 
foreign body-related chronic inﬂ ammatory reaction.
In a randomized, double-blinded study (Narins et al 
2003) in which 138 patients received both Restylane and 
glutaraldehyde-cross linked bovine collagen (Zyplast, 
McGhan Medical Inc., Santa Barbara, California) on 
contralateral nasolabial folds, the frequency, intensity and 
duration of injection site reactions were similar for both 
products. Delayed onset reactions, primarily consisting of 
localized skin redness which resolved without treatment 
within 2–3 months, were noted in 8% of patients treated 
with Restylane.
A review (Friedman et al 2002) of all reports of adverse 
reactions to Restylane submitted to the manufacturer in 
1999 and 2000, representing an estimated 306,000 treated 
patients, documented one adverse event for every 650 to 
1800 patients treated. These reactions consisted primarily 
of localized hypersensitivity reactions. There were two 
cases of injection site necrosis in the glabellar area, as 
well as “rare reports of localized granulomatous reactions, 
bacterial infections, acneiform and cystic lesions”. The 
exact number and type of “adverse reactions” was not fully 
detailed. The authors acknowledged that: (i) the number 
of total patients treated may have been overestimated, as 
the number was projected based on the total number of 
syringes of Restylane sold during this time period; and 
(ii) the total number of adverse reactions may have been 
under-reported by clinicians.
A retrospective study (Andre 2004) of an estimated 
4300 patients treated with Restylane documented an over-
all incidence of hypersensitivity of 0.8%, almost equally 
divided between immediate and delayed reactions. It was 
noted that the incidence of adverse reactions decreased 
to approximately 0.6% from 2000 to 2001. The authors 
attributed this decrease to a reduction in the amount of 
protein in the raw product secondary to improvements in 
the manufacturing process. Overall, 18 delayed reactions, 
appearing between several weeks to 6 months after treat-
ment, were documented. Most presented as nodules with 
associated erythema of the overlying skin. Three “sterile 
abscesses” were noted.
In a prospective randomized study of 38 individuals 
treated with Restylane alone or Restylane with Botulinum 
toxin A (Carruthers and Carruthers 2003), one subject in the 
combined Restylane/Botulinum toxin A group developed 
delayed erythema, swelling and discomfort at the injection 
site at 4 and 11 months.
A review of 709 patients (Lowe et al 2001) treated with 
either Hylaform or Restylane for smoothing of nasolabial 
and glabellar lines, lip augmentation and correction of 
atrophic facial scars, demonstrated an incidence of delayed 
skin reactions of slightly less than 0.5%. These reactions, 
ﬁ rst noticed between 6 to 8 weeks after injection, were of 
varying severity and manifested as injection site induration, 
erythema and tenderness. One patient developed “a sterile 
abscess” of the nasolabial region. Time to complete resolu-
tion varied from 6 to 24 weeks. Three patients were treated 
with intralesional injections of triamcinolone. Subsequent 
intradermal skin testing for hyaluronic acid was positive in 
4 of 5 patients tested.
Most examples of adverse reactions following dermal 
inﬁ ltration with hyaluronic acid-based ﬁ llers have been in 
the form of individual case reports (eg, Jordan 2005). Lupton 
and Alster (Lupton and Alster 2000) reported on a woman 
who developed multiple erythematous papulocystic nodules 
following injection of an unspeciﬁ ed “modiﬁ ed hyaluronic 
acid gel”. The patient declined a biopsy. Another patient 
was described (Shaﬁ r et al 2000) who developed multiple 
“sterile abscesses” following injection of her lips and naso-
labial folds with Restylane. Two of these lesions ruptured 
spontaneously, whereas the remainder required surgical 
excision. A similar case was described (Wolfram et al 2006) 
of another patient who developed multiple foreign body reac-
tions following treatment with Restylane that also required 
surgical intervention to adequately manage. Patel and col-
leagues (2006) presented the case of a 65-year old woman 
who developed a hypersensitivity reaction following at least 
four previous treatments with Restylane. The reaction was 
characterized by severe injection site erythema, edema and 
induration. Interestingly, this patient had undergone a single 
negative intradermal Restylane challenge test in the forearm 
prior to undergoing the cosmetic procedures. The authors 
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acknowledged that, in retrospect, the patient should have 
undergone a conventional double skin test.
Histologic examination of dermally 
implanted hyaluronic acid
In an in vivo study in rats (Fernandez-Cossio and Castano-
Oreja 2006), subcutaneous injection of Restylane was char-
acterized by an acute inﬂ ammatory response within the ﬁ rst 
4 weeks. At 8 months, there was little evidence of biodeg-
radation. The implanted hyaluronic acid remained walled 
off from the surrounding tissue by a capsule consisting of 
collagen and ﬁ broblasts. Minimal inﬁ ltration of cells into 
the implant was noted and there was no connective tissue 
formation within the implant. Inﬂ ammation was minimal. 
An in vivo rabbit histologic study of a new modiﬁ ed hyal-
uronic acid ﬁ ller, in which hyaluronic acid molecules were 
cross-linked by an esteriﬁ cation reaction without introduc-
tion of another chemical agent (Alessandrini et al 2006), 
demonstrated intense macrophage-mediated phagocytosis 
of the injected ﬁ ller. No evidence of persistent inﬂ amma-
tion or granulomatous reaction was noted. One intradermal 
animal study (Sasaki et al 2003) with hylan (Synvisc), 
a chemically-modiﬁ ed hyaluronic acid injectable that is 
widely used to treat knee pain associated with degenerative 
osteoarthritis, resulted in severe foreign body-type granulo-
matous inﬂ ammation in guinea pigs. Although antibodies 
against hylan were described, no evidence of an antibody 
reaction directed against pure, unmodiﬁ ed hyaluronic acid 
was noted.
Few studies have documented histologic evidence of the 
in vivo longevity or adverse reactions to chemically-modiﬁ ed 
hyaluronic acid dermal injections in human subjects. One 
of the most comprehensive histopathologic assessments of 
adverse reactions following injection of cosmetic ﬁ llers was 
reported by Lombardi and colleagues (2004). Biopsies 
obtained from patients injected with Dermalive, which 
consists of 60% pure hyaluronic acid and 40% acrylic 
hydrogel, revealed classic foreign body giant cell-type 
granulomas. However, none of the patients biopsied in this 
study had been treated with hyaluronic acid-derived ﬁ llers 
alone.
Lamperle and colleagues (2003) examined tissue from 
several different injectable ﬁ llers, including Restylane, fol-
lowing intradermal inﬁ ltration into the volar forearm. Time 
periods ranged from 1–9 months. The authors concluded 
that although all substances tested appeared to be clinically 
safe, all exhibited some degree of undesirable side effects. In 
another study (Parada et al 2005), histologic specimens were 
obtained following adverse reactions to 6 different dermal 
ﬁ llers, including Restylane.
Most reports have described the presence of foreign 
body-type granulomatous reactions, although injection 
site reactions characterized by lymphoplasmacytic chronic 
inflammatory-type reactions have also been described 
(eg, Lowe et al 2001). Micheels (2001) documented 8 cases 
of delayed reactions to both Restylane and Hylaform in 219 
patients treated with one or both of these products. These 
patients subsequently underwent intradermal testing with 
both Hylaform and Restylane preparations that had been 
pretreated with hyaluronidase. Biopsy results were reported 
from either the dermal testing site or the original facial site 
of injection on 4 of these patients. Findings ranged from 
classic foreign body-type giant cell granulomas (3 Hylaform, 
1 Restylane) to chronic inﬂ ammation (1 Restylane). Although 
Micheels’s reference to “anti-hyaluronic acid antibodies” 
has been widely reported in a number of other manuscripts, 
these ﬁ ndings have been criticized by others (Klein 2005) 
for several reasons, including that fact that the speciﬁ city of 
these antibodies to HA was not conﬁ rmed and the observation 
that hyaluronidase-treated preparations were used to elicit 
the reaction instead of unmodiﬁ ed ﬁ ller.
Fernandez-Acenero and colleagues (2003) reported a 
48-year old woman who developed a nodule of the upper lip 
2 months after receiving a single injection of Restylane. On 
biopsy, this was characterized as a foreign body-type giant 
cell granulomatous reaction surrounding a pool of amorphous 
material consistent with unresorbed HA.
Raulin and colleagues (2000) performed skin testing on 
a 53 year-old woman who developed a granulomatous-like 
lesion after injection of Hylaform for correction of perioral 
wrinkles. A biopsy taken from the cutaneous test site after 
30 days revealed the presence of a foreign body granuloma 
as well as the presence of mucin-like basophilic material 
presumed to be Hyalform. In a similar case (Rongioletti 
et al 2003), biopsy on a 72-year-old woman who developed 
induration of the skin after receiving injections of Restylane 
revealed a foreign body granulomatous reaction encircling 
clear spaces of variable size. Alcian blue positive material 
was identiﬁ ed in the sclerotic stroma, but not in the clear 
vacuolated areas. Due to the histologic resemblance of 
the biopsied specimen to a silicone foreign body reaction, 
infrared spectrophotometry was performed to rule out the 
possibility of adulteration of the injected ﬁ ller with silicone. 
This case was unusual because, during the same period, the 
patient was diagnosed with scleromyxedema, a rare connec-
tive tissue disorder of unknown etiology characterized by 
Clinical Interventions in Aging 2007:2(4)514
Edwards and Fantasia
the presence of excessive hyaluronic acid deposition in the 
dermis coupled with the presence of abnormal paraprotein. 
A direct association between these two ﬁ ndings could not be 
conﬁ rmed.
Other examples (Honig et al 2003) have included a 
woman who developed a foreign body-type giant cell 
reaction following injections of hyaluronic acid to the 
nasolabial fold, and a 41 year old woman who devel-
oped multiple indurated, erythematous injection site 
nodules 5 weeks after receiving her ﬁ rst treatment with 
Restylane in the nasolabial, glabellar and periorbital areas 
(Ghislanzoni et al 2006). Histologic examination in the 
latter case revealed the presence of honeycomb-shaped 
basophilic material, presumed to represent hyaluronic 
acid gel, surrounded by a foreign body giant cell-type 
granulomatous reaction.
Dal Sacco and colleagues (2005) described a patient 
who developed multiple tender nodules in the nasolabial 
fold 4 months after injection of Restylane. Biopsy revealed 
the presence of sarcoid-like granulomas. Interestingly, the 
patient also developed similar-appearing dermal lesions 
at previous sites of venipuncture and scarring. On further 
diagnostic workup, the patient was diagnosed with sarcoid-
osis. Based on the extent of her clinical disease and the 
presentation of dermal lesions in multiple sites of previous 
skin trauma, it was concluded that the hyaluronic acid injec-
tions triggered a sarcoidal skin reaction in a background 
of a pre-existing but subclinical case of sarcoidosis (“scar 
sarcoidosis”).
We previously reported (Edwards et al 2006) a case of 
a 74-year-old woman who presented with a 1.5 cm, ﬁ rm, 
submucosal nodule of the lower lip that was clinically 
Figure 1 Low power view of biopsy specimen from lower lip from a 74-year-old woman who presented with a submucosal nodule of the lower lip. The patient had 
received injections of Restylane to the lips approximately 6 months before. Histologic examination of the biopsied specimen revealed the presence of multiple vacu-
olated, cyst-like areas. These are surrounded by a fi brotic connective tissue capsule and a tissue reaction composed predominantly of histiocytes and foamy macrophages. 
(Hematoxylin and eosin, original magnifi cation 10x).
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thought to represent a benign minor salivary gland neoplasm. 
Histologic examination (Figures 1 and 2) of the biopsied 
specimen revealed the presence of multiple vacuolated 
cyst-like areas, surrounded by a granulomatous foreign body 
reaction composed predominantly of histiocytes, foamy mac-
rophages and lymphocytes. Multinucleated giant cells were 
also noted (Figure 3). On subsequent questioning, the patient 
acknowledged that she had received injections of Restylane 
to the lips by a dermatologist approximately 6 months before 
the development of the nodule, but had failed to mention this 
because she didn’t think that these two events were related. 
The patient denied having any additional cosmetic procedures 
to the face or lips other than the Restylane injection.
Although the clinical longevity of hyaluronic acid-derived 
products appears to be in the range of 4 to 6 months in most 
dermal applications, there is evidence that the tissue longev-
ity of these products may be substantially longer. In one 
case (Bennet and Taher 2005), the continued presence of 
Restylane was documented in the dermis of the lip 23 months 
post-implantation. Soparkar and colleagues (2004) performed 
an incisional biopsy on a 65-year-old female patient who 
developed multiple plaque-like elevations of the periorbital 
region 5 years after undergoing cosmetic treatment with 
Restylane. Histologic examination revealed the presence of 
multiple cyst-like spaces, some of which contained alcian 
blue positive material, with a surrounding ﬁ brotic reaction. 
Interestingly, these dermal elevations disappeared following 
the local inﬁ ltration of hyaluronidase, suggesting that at least 
in some cases the presence of excessive volumes of injected 
hyaluronic acid may play a role in the development of these 
late reactions.
Very little has been published regarding the more recently 
introduced NASHA materials Captique and Juvederm. There 
is one case in the literature (Matarasso and Herwick 2006) 
Figure 2 High power view of biopsy specimen from lower lip. Fibrotic tissue and abundant histiocytes surround the vacuolated areas. (Hematoxylin and eosin, original 
magnifi cation 40x).
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of a 52-year old woman who developed biopsy-conﬁ rmed 
foreign body injection site granulomas several weeks after 
injections of Captique to the nasolabial folds and perioral 
area. These resolved spontaneously after 6 months.
Treatment of hyaluronic
acid-related late reactions
Treatment options for patients presenting with delayed 
hypersensitivity reactions range from simple observation to 
local treatment with topical corticosteroids or intralesional 
injection of corticosteroids. Lesions that fail to resolve 
with conservative therapy may beneﬁ t from treatment with 
systemic therapy with corticosteroids, although in some 
case surgical intervention may ultimately be required. 
Intralesional administration of hyaluronidase has also been 
successfully employed to resolve nodular lesions (Soparkar 
and Patrinely 2005). Recently, etanercept, an inhibitor of 
tumor necrosis factor-alpha activity, has been used to resolve 
lesions in patients with silicone granulomas (Desai et al 
2006), although its use in treating patients presenting with 
delayed hypersensitivity reactions to hyaluronic acid has not 
been documented to date.
Pathogenesis of foreign body 
reactions to hyaluronic acid-based 
dermal fi llers
Injection of any foreign material into the dermis triggers an 
inﬂ ammatory response; essentially a protective response 
intended to eliminate the initial cause of cell injury as well 
as to repair any tissue damaged as a result of the original 
insult. The initial phase, lasting from several hours to days, 
is characterized by an acute inﬂ ammatory process localized 
to the injection site. The hallmark of acute inﬂ ammation 
involves circulatory changes leading to the release of soluble 
mediators of inﬂ ammation, and chemotaxis of neutrophils to 
the site of injury. If these areas of acute inﬂ ammation fail to 
Figure 3 High power view of biopsy specimen from lower lip.  A multinucleated foreign body-type giant cell is visible in the center of the photomicrograph. (Hematoxylin 
and eosin, original magnifi cation 60x).
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resolve and become walled off, abscess formation ensues. 
By deﬁ nition, an abscess is deﬁ ned as an acute inﬂ ammatory 
process characterized by a localized collection of dead and 
dying neutrophils surrounding a foreign agent or organism.
Long term tissue reactions to any unresorbed foreign 
material are generally characterized by a chronic inﬂ amma-
tory reaction, consisting of an inﬁ ltration of mononuclear 
cells (eg, macrophages, lymphocytes and plasma cells) 
and attempts at healing characterized by the formation of 
a collagen capsule and/or granulation tissue. Many late-
occurring adverse reactions to injectable dermal agents most 
likely represent localized foreign body-type granulomatous 
inﬂ ammation. Granulomatous inﬂ ammation represents a 
speciﬁ c type of chronic inﬂ ammation caused by antigens 
that evoke cell-mediated hypersensitivity (eg, tuberculosis) 
or agents that persist at site of inﬂ ammation (eg, foreign 
bodies). The histologic presentation of granulomatous 
inﬂ ammation is composed of modiﬁ ed macrophages, termed 
epithelioid macrophages, which can occasionally fuse to form 
“foreign body-type” multinucleated giant cells, as well as 
T-lymphocytes, occasional plasma cells, and a proliferation 
of ﬁ broblasts and capillaries. The epithelioid macrophages 
are typically found adherent to the implant surface, contribut-
ing to the formation of a soft tissue capsule.
In the dermatologic literature, the term “sterile abscess” 
is broadly used to describe a nodular lesion that has formed 
as a result of foreign bodies and/or injected medications that 
have not been totally absorbed. In many cases, these “sterile 
abscesses” represent a chronic inﬂ ammatory granulomatous 
reaction. From a cosmetic point of view, surgical treatment 
to evacuate the contents of the “sterile abscess” may be 
required to reduce the likelihood of indurated scar-like tissue 
forming (Lowe et al 2005).
The exact cause of these chronic inﬂ ammatory reactions 
following the injection of chemically-modified hyal-
uronic acid ﬁ llers has been debated. The literature in this 
area makes extensive reference to the fact that, because 
hyaluronic acid is identical across species, these products 
are not recognized as foreign by the body and therefore 
should not trigger any long-term inﬂ ammatory response. 
However, as reviewed in this manuscript, it is apparent 
that although the risk of developing a clinically evident 
host reaction is limited, numerous cases have neverthe-
less been documented. The most widely accepted view 
is that these late side effects are related to contamination 
by residual bacterial and or avian proteins from the pro-
duction process. These products do indeed contain trace 
amounts of hyaluronin-associated protein and, in the case 
of Restylane, streptococcus equi-derived bacterial antigens 
(Andre 2004). The documented decrease in the incidence 
of late adverse reactions following improvements in the 
Restylane manufacturing process, resulting in a substantial 
decrease in protein contaminants, has been widely cited in 
support of this theory (Friedman et al 2002).
Another possible explanation may lie in the chemical 
cross-linking process that is used to increase the clinical 
half-life of these products compared to that of native hyal-
uronic acid. While remnants of the chemical agents used 
in the cross-linking (“stabilizing”) process could trigger 
a delayed inﬂ ammatory reaction, it is more likely that the 
chemical cross-linking process itself, which reportedly 
modifies the structure by 0.6%–1.0%, (Andre 2004), 
introduces an immunogenic potential by inducing changes 
in the three dimensional structure of these molecules. 
The breakdown products of these chemically-modiﬁ ed 
hyaluronic acids could also be a cause of the immunologic 
response. Alternatively, these breakdown products could 
themselves be further metabolized to other immunogenic 
compounds (Coleman 2005).
The possibility that some of these long-term side effects 
could be in part technique-related, for example related to 
local deposition of excessive tissue volumes of hyaluronic 
acid, cannot be entirely discounted.
Of interest is the observation that, in vivo, hyaluronic 
acid is depolymerized into lower molecular weight frag-
ments by enzymatic digestion. Even more intriguing are 
recent ﬁ ndings that hyaluronic acid and its degradation 
products are important regulators of dendritic cells and mac-
rophages (Termeer et al 2003). Hyaluronic acid degradation 
products are potent activators of macrophages through the 
CD44 cell surface receptors (Leonhardt et al 2005), while 
dendritic antigen-presenting cells and T-cells appear to 
regulate the synthesis and degradation of hyaluronic acid 
directly by synthesizing hyaluronic acid synthetases and 
hyaluronidases. Although only speculation, it is plausible 
that changes in the balance between high molecular weight 
hyaluronic acid and its degradation products in a local 
microenvironment, induced by the injection of chemically-
modiﬁ ed hyaluronic acid particles (with altered degradation 
kinetics) could lead to altered T-cell and/or macrophage 
activation and hence granuloma formation in a certain 
subset of patients.
Conclusions
Although chemically-modified hyaluronic acid dermal 
ﬁ llers, both animal and nonanimal source, have a very low 
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incidence of long term side effects, patients need to be 
informed of the potential risk of foreign body reactions to 
these injectable agents.
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